Syncria albiglutide: Additional Phase III data

Additional data from the open-label, international Phase III Harmony 7 trial in 841 Type II diabetics showed that once-weekly subcutaneous albiglutide met the secondary endpoint of a significantly greater proportion of patients achieving HbA1c <7% at week 32 vs. once-daily 1.8 mg Victoza liraglutide (52% vs. 42%, p=0.0023). Albiglutide also met the secondary endpoint of significantly reducing FPG from baseline to week 32 vs. Victoza (22 vs. 30 mg, p=0.0050). Data were presented at the American Diabetes Association meeting in Philadelphia. ...